The European Union’s medicines regulator said Friday it had started a “rolling review” of a COVID-19 vaccine developed by German firm CureVac, the first step towards a possible authorisation in the bloc.
“Preliminary results from laboratory studies and early clinical studies in adults… suggest the vaccine triggers the production of antibodies and immune cells that target” the coronavirus, the European Medicines Agency (EMA) said in a statement.
The rolling review of CureVac’s shot will continue “until enough evidence is available for a formal marketing authorisation application”, it added.
With delays to deliveries of three already-authorised vaccines, the EMA is under pressure from the EU’s 27 member states to speed more into service.Read:Coronavirus reinfections are real. Here’s what that means for controlling the pandemic
CureVac’s messenger RNA vaccine is currently undergoing large-scale Phase 3 trials, and would be produced by pharma giant Bayer if approved.
“If all goes well, EMA authorisation could come in April,” Professor Peter Kremsner of the Tuebingen Institute of Tropical Medicine, who is supervising the trial, told German television.
The EMA itself said only that authorisation “should take less time than normal” thanks to the rolling review process, which is also being applied to the Novavax and Johnson and Johnson vaccines.Read:When it comes to accepting the COVID vaccine, it’s Australia’s fence-sitters we should pay attention to
Follow the latest news on the coronavirus (COVID-19) outbreak
© 2021 AFPRead:HCQ has no significant impact on heart rhythm in lupus patients, even those with CKD
EU regulator opens review into CureVac’s COVID shot (2021, February 12)
retrieved 12 February 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.